Immune Thrombocytopenia Second-Line Therapy

Introduction to Second-Line Therapy

For patients with immune thrombocytopenia requiring second-line therapy, TPO receptor agonists (TPO-RAs) should be considered the preferred treatment option over rituximab, particularly in patients who have had ITP for more than one year 1

TPO-RAs should be considered the primary second-line therapy for most patients who have had ITP for more than one year due to their superior long-term efficacy and safety profile 1
The American Society of Hematology recommends that rituximab use in ITP should be reevaluated and limited due to lack of significant long-term benefits in most patients, variable and unpredictable time to response, reduced efficacy in male patients and those with ITP duration >1 year, and potential risks associated with immunosuppression 1

The American College of Physicians recommends assessing duration of ITP, with TPO-RAs preferred for ITP duration >1 year and consideration of both options for ITP duration <1 year 1
Patient factors such as male patients, where TPO-RAs are preferred due to reduced efficacy of rituximab, and female patients, where either option may be considered, should be taken into account when selecting second-line therapy 1

The American Society of Hematology recommends using the minimum TPO-RA dose necessary to maintain target platelet count and prevent bleeding, and considering holding therapy and monitoring for remission for patients achieving target platelet count at lowest recommended dose 1
If a patient doesn't respond to or tolerate one TPO-RA, switching to an alternate TPO-RA is often effective, and abrupt interruptions or excessive dose adjustments that may cause platelet fluctuations should be avoided 1

The American College of Physicians recommends avoiding overuse of rituximab, prolonged corticosteroid use, inappropriate dose adjustments, and failure to monitor for remission in patients with ITP 1